Dr. Clay Siegall’s work with Cancer Research

Clay B. Siegall, Ph.D., is the President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc., a biotechnology company. Siegall who received his Ph.D. in Genetics from George Washington University and his Zoology degree from the University of Maryland co-founded Seattle Genetics in 1998. Seattle Genetics is based on a strong passion to help others along with sound scientific research, and drug development practices.

Dr. Clay B. Siegall is the driving force behind the success of Seattle Genetics. His leadership skills has helped his company take its position in the forefront developing antibody-drug conjugates(ADCs) and securing the FDAs approval of its ADC product ADCETRIS (brentuximab vedotin)in 2011. Seattle Genetics in collaboration with Takeda Pharmaceutical Company and ADCETRIS is now a global brand that has been approved in more than 60 countries.

Seattle Genetics has generated more than 325 million dollars entering into multiple strategic licenses with GlaxoSmithKline and Pfizer Genentech (Roche), AbbVie, for its ADC technology. Seattle Genetics is in the forefront in antibody-drug conjugates (ADCs), a technology specifically designed to harness the targeting ability of monoclonal antibodies to deliver cell killing agents directly to cancer cells thus sparing non-targeted cells.

Prior to his accomplishments with Seattle Genetics, Clay B. Siegall was with Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute from 1991 to 1997, and The National Institutes of Health from 1988 to 1991. Dr. Siegall is an author of over 70 publications, holds 15 patents and is a recipient of numerous awards. Dr. Siegall joined as a board member of Ultragenyx in 2014 and also serves on the Boards of Directors of Alder BioPharmaceuticals, Inc., a publicly-traded biotechnology company, and Mirna Therapeutics, Inc., a privately-held biotechnology company.

Among the many awards that Dr. Clay B. Siegall has received, are the 2013 University of Maryland Alumnus of the year for Computer, Math and Natural Sciences, and the 2012 Pacific Northwest Ernst and Young Entrepreneur of the Year. Seattle Genetics, co-founded by Dr. Clay B. Siegall continues to develop and commercialize innovative monoclonal antibody-based therapy for the treatment of cancer.